FDA Inspection 1002560 — Euridiki Drogari
The FDA completed an inspection of Euridiki Drogari on Feb 9, 2017 in Athens. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Feb 9, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Athens (Greece)
Additional Details
Clinical Investigator (CI)